Please login to the form below

Not currently logged in
Email:
Password:

UDG buys Galliard and Nyxeon

Will add UK comms firms to Ashfield Healthcare Communications division
UDG Healthcare

Marketing firm UDG Healthcare has added to its growing list of business with the acquisition of the agencies Galliard and Nyxeon.

Dublin-headquartered UDG will spend a maximum of £13m for the two agencies' parent company MFRHRC Holdings, payable over the next three years.

Specialist healthcare and scientific PR businesses Galliard and Nyxeon will sit within UDG's global healthcare communications business, Ashfield Healthcare Communications. Their acquisition adds capabilities in data driven healthcare and scientific public relations to the growing UDG portfolio.

London-based Galliard and Nyxeon employ 33 people, providing services to global pharmaceutical companies, healthcare-related organisations and charities. Services offered include: media relations, issues management, scientific and medical education, and corporate and employee communications.

Commenting on the announcement, Roland Carreras, managing partner of Galliard said: “We are delighted to be joining Ashfield Healthcare Communications, which is becoming a powerhouse in healthcare sales and marketing.”

“The deal sets the scene for the next stage in our growth and we look forward to working with Ashfield's strong stable of medical education agencies.”

Liam Fitzgerald, UDG's chief executive, said that he was delighted to announce the acquisition.

“This purchase is fully aligned with our global growth strategy of extending the range of services we offer in high value multichannel healthcare communications and follows the successful acquisitions of InforMed, Watermeadow and more recently, Knowledgepoint360.”

11th July 2014

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...